Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons

J Infect Dis. 2011 Jan 1;203(1):117-21. doi: 10.1093/infdis/jiq013.

Abstract

Recent in vitro studies suggest that acyclovir may directly inhibit HIV-1 replication and can select for a specific HIV-1 reverse transcriptase mutation (V75I) with concomitant loss of an anti-HIV-1 effect. We tested for HIV-1 genotypic resistance at reverse transcriptase codon 75 in plasma from 168 HIV-1-infected persons from Botswana, Kenya, Peru, and the United States taking daily acyclovir or valacyclovir for between 8 weeks and 24 months. No V75I cases were detected (95% confidence interval, 0%-2.2%). These prospective in vivo studies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acyclovir / administration & dosage*
  • Acyclovir / analogs & derivatives*
  • Acyclovir / pharmacology
  • Adult
  • Amino Acid Substitution / genetics
  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / pharmacology
  • Botswana
  • Drug Resistance, Viral*
  • Female
  • HIV Infections / complications*
  • HIV Infections / virology
  • HIV Reverse Transcriptase / genetics
  • HIV-1 / drug effects*
  • HIV-1 / genetics
  • HIV-1 / isolation & purification
  • Herpes Genitalis / complications*
  • Herpes Genitalis / drug therapy
  • Herpes Genitalis / virology
  • Herpesvirus 2, Human / isolation & purification
  • Humans
  • Kenya
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Mutation, Missense
  • Peru
  • Point Mutation
  • Prospective Studies
  • Selection, Genetic
  • Sequence Analysis, DNA
  • United States
  • Valacyclovir
  • Valine / administration & dosage
  • Valine / analogs & derivatives*
  • Valine / pharmacology

Substances

  • Antiviral Agents
  • reverse transcriptase, Human immunodeficiency virus 1
  • HIV Reverse Transcriptase
  • Valine
  • Valacyclovir
  • Acyclovir

Associated data

  • GENBANK/HQ257146
  • GENBANK/HQ257147
  • GENBANK/HQ257148
  • GENBANK/HQ257149
  • GENBANK/HQ257150
  • GENBANK/HQ257151
  • GENBANK/HQ257152
  • GENBANK/HQ257153
  • GENBANK/HQ257154
  • GENBANK/HQ257155
  • GENBANK/HQ257156
  • GENBANK/HQ257157
  • GENBANK/HQ257158
  • GENBANK/HQ257159
  • GENBANK/HQ257160
  • GENBANK/HQ257161
  • GENBANK/HQ257162
  • GENBANK/HQ257163
  • GENBANK/HQ257164
  • GENBANK/HQ257165
  • GENBANK/HQ257166
  • GENBANK/HQ257167
  • GENBANK/HQ257168
  • GENBANK/HQ257169
  • GENBANK/HQ257170
  • GENBANK/HQ257171
  • GENBANK/HQ257172
  • GENBANK/HQ257173
  • GENBANK/HQ257174
  • GENBANK/HQ257175
  • GENBANK/HQ257176
  • GENBANK/HQ257177
  • GENBANK/HQ257178
  • GENBANK/HQ257179
  • GENBANK/HQ257180
  • GENBANK/HQ257181
  • GENBANK/HQ257182
  • GENBANK/HQ257183
  • GENBANK/HQ257184
  • GENBANK/HQ257185
  • GENBANK/HQ257186
  • GENBANK/HQ257187
  • GENBANK/HQ257188
  • GENBANK/HQ257189
  • GENBANK/HQ257190
  • GENBANK/HQ257191
  • GENBANK/HQ257192
  • GENBANK/HQ257193
  • GENBANK/HQ257194
  • GENBANK/HQ257195
  • GENBANK/HQ257196
  • GENBANK/HQ257197
  • GENBANK/HQ257198
  • GENBANK/HQ257199
  • GENBANK/HQ257200
  • GENBANK/HQ257201
  • GENBANK/HQ257202
  • GENBANK/HQ257203
  • GENBANK/HQ257204
  • GENBANK/HQ257205
  • GENBANK/HQ257206
  • GENBANK/HQ257207
  • GENBANK/HQ257208
  • GENBANK/HQ257209
  • GENBANK/HQ257210